Profile data is unavailable for this security.
About the company
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. It is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.
- Revenue in USD (TTM)0.00
- Net income in USD-32.94m
- Incorporated2002
- Employees44.00
- LocationTourmaline Bio Inc27 West 24th Street, Suite 702NEW YORK 10010United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://www.tourmalinebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALX Oncology Holdings Inc | 0.00 | -166.20m | 350.63m | 74.00 | -- | 2.06 | -- | -- | -3.71 | -3.71 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -67.73 | -34.34 | -76.12 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.067 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| AC Immune SA | 16.64m | -61.36m | 361.58m | 133.00 | -- | 2.22 | -- | 21.73 | -0.6881 | -0.6881 | 0.1873 | 1.64 | 0.088 | -- | 61.04 | 125,110.40 | -32.45 | -18.25 | -35.04 | -19.52 | -- | -- | -368.77 | -148.29 | -- | -- | 0.0225 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Tscan Therapeutics Inc | 14.81m | -96.80m | 364.22m | 161.00 | -- | 2.68 | -- | 24.59 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 177.60m | -4.89m | 368.98m | 203.00 | -- | 0.6783 | -- | 2.08 | -0.0846 | -0.0846 | 3.08 | 9.35 | 0.2738 | 10.32 | 5.80 | 874,896.60 | -0.7538 | 6.61 | -0.8808 | 7.62 | 92.42 | 90.55 | -2.75 | 15.18 | 4.69 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Lexeo Therapeutics Inc | 0.00 | -69.42m | 380.19m | 58.00 | -- | 2.08 | -- | -- | -2.71 | -2.71 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -47.71 | -- | -54.30 | -- | -- | -- | -- | -- | -- | -- | 0.0091 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -115.28m | 389.10m | 33.00 | -- | 1.60 | -- | -- | -4.70 | -4.70 | 0.00 | 5.50 | 0.00 | -- | -- | 0.00 | -76.12 | -- | -82.46 | -- | -- | -- | -- | -- | -- | -2.15 | 0.0856 | -- | -- | -- | -260.87 | -- | -- | -- |
| Tourmaline Bio Inc | 0.00 | -32.94m | 395.21m | 44.00 | -- | 1.12 | -- | -- | -5.35 | -5.35 | 0.00 | 13.81 | 0.00 | -- | -- | 0.00 | -12.39 | -- | -12.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -42.44m | 399.50m | 67.00 | -- | 2.07 | -- | -- | -1.90 | -1.90 | 0.00 | 7.18 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | -31.02 | -- | -- | -- |
| Organogenesis Holdings Inc | 435.47m | 5.82m | 400.37m | 862.00 | 69.46 | 1.43 | 18.86 | 0.9194 | 0.0435 | 0.0435 | 3.28 | 2.11 | 0.9628 | 4.08 | 4.63 | 505,190.30 | 1.29 | 5.46 | 1.56 | 6.90 | 75.07 | 74.94 | 1.34 | 4.81 | 2.41 | 8.78 | 0.1955 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Lyell Immunopharma Inc | 68.00k | -228.34m | 415.55m | 224.00 | -- | 0.6889 | -- | 6,111.04 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -75.92m | 418.65m | 100.00 | -- | 1.16 | -- | -- | -1.73 | -1.73 | 0.00 | 8.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0045 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Ocugen Inc | 7.05m | -58.50m | 422.06m | 65.00 | -- | 13.95 | -- | 59.87 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| C4 Therapeutics Inc | 20.04m | -126.07m | 423.84m | 145.00 | -- | 1.64 | -- | 21.15 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Editas Medicine Inc | 69.41m | -166.13m | 428.46m | 265.00 | -- | 1.46 | -- | 6.17 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Taysha Gene Therapies Inc | 14.16m | -118.01m | 439.01m | 52.00 | -- | 7.57 | -- | 31.01 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Data as of Jul 23 2024. Currency figures normalised to Tourmaline Bio Inc's reporting currency: US Dollar USD
48.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 2.22m | 8.67% |
| RA Capital Management LPas of 23 May 2024 | 2.05m | 7.97% |
| Deep Track Capital LPas of 31 Mar 2024 | 1.60m | 6.22% |
| Cormorant Asset Management LPas of 31 Mar 2024 | 1.25m | 4.87% |
| Jennison Associates LLCas of 31 Mar 2024 | 1.12m | 4.35% |
| QVT Financial LPas of 31 Mar 2024 | 948.37k | 3.70% |
| Braidwell LPas of 31 Mar 2024 | 906.82k | 3.54% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 896.73k | 3.50% |
| RTW Investments LPas of 31 Mar 2024 | 741.66k | 2.89% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 700.91k | 2.73% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
